APO Research
Talk to an analyst

APO RESEARCH · REPORT

Overactive Bladder (OAB) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Overactive Bladder (OAB) Therapeutics Industry Growth and Trends Forecast to 2032

20 December 2025104 pages

Choose your research edition.

Industry ResearchOveractive Bladder (OAB) Therapeutics Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Overactive Bladder (OAB) Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Overactive Bladder (OAB) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Overactive Bladder (OAB) Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Overactive Bladder (OAB) Therapeutics Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Overactive Bladder (OAB) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Overactive Bladder (OAB) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Overactive Bladder (OAB) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Overactive Bladder (OAB) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Overactive Bladder (OAB) Therapeutics include Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Ion Channel Innovations, Kwang Dong Pharmaceutical, ONO Pharmaceutical, Tengion, GlaxoSmithKline and Ferring, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Overactive Bladder (OAB) Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Overactive Bladder (OAB) Therapeutics market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Overactive Bladder (OAB) Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Overactive Bladder (OAB) Therapeutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Overactive Bladder (OAB) Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Overactive Bladder (OAB) Therapeutics Market by Company

Allergan

Astellas Pharma

Hisamitsu Pharmaceutical

Ion Channel Innovations

Kwang Dong Pharmaceutical

ONO Pharmaceutical

Tengion

GlaxoSmithKline

Ferring

Pfizer

Lanzhou Institute of Biological Products

Merck

Sanofi

Teva Pharmaceutical Industries

Overactive Bladder (OAB) Therapeutics Segment by Type

Anticholinergic Agents

Beta-3 Adrenoreceptor Agonists

Overactive Bladder (OAB) Therapeutics Segment by Application

Hosptial

Clinci

Other

Overactive Bladder (OAB) Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Overactive Bladder (OAB) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Overactive Bladder (OAB) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Overactive Bladder (OAB) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Overactive Bladder (OAB) Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Overactive Bladder (OAB) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Anticholinergic Agents Table 2. Major Company of Beta-3 Adrenoreceptor Agonists Table 3. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 5. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Type (2021-2026) Table 6. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 7. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Type (2021-2026) Table 8. Global Overactive Bladder (OAB) Therapeutics Price by Type (2021-2026) & (US$/Unit) Table 9. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2027-2032) & (K Units) Table 10. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Type (2027-2032) Table 11. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2027-2032) & (US$ Million) Table 12. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Type (2027-2032) Table 13. Global Overactive Bladder (OAB) Therapeutics Price by Type (2027-2032) & (US$/Unit) Table 14. North America Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 15. North America Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 17. Europe Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 21. Latin America Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 24. Overactive Bladder (OAB) Therapeutics Industry Trends Table 25. Overactive Bladder (OAB) Therapeutics Industry Drivers Table 26. Overactive Bladder (OAB) Therapeutics Industry Opportunities and Challenges Table 27. Overactive Bladder (OAB) Therapeutics Industry Restraints Table 28. Global Overactive Bladder (OAB) Therapeutics Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Company (2021-2026) Table 30. Global Overactive Bladder (OAB) Therapeutics Sales by Company (2021-2026) & (K Units) Table 31. Global Overactive Bladder (OAB) Therapeutics Sales Share by Company (2021-2026) Table 32. Global Overactive Bladder (OAB) Therapeutics Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Overactive Bladder (OAB) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Overactive Bladder (OAB) Therapeutics Major Company Production Sites and Headquarters Table 35. Global Overactive Bladder (OAB) Therapeutics Company, Product Type & Application Table 36. Global Overactive Bladder (OAB) Therapeutics Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Overactive Bladder (OAB) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Overactive Bladder (OAB) Therapeutics Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2021-2026) & (K Units) Table 41. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Region (2021-2026) Table 42. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2021-2026) & (US$ Million) Table 43. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Region (2021-2026) Table 44. Global Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2027-2032) & (K Units) Table 46. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Region (2027-2032) Table 47. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2027-2032) & (US$ Million) Table 48. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Region (2027-2032) Table 49. Global Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 52. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Application (2021-2026) Table 53. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 54. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Application (2021-2026) Table 55. Global Overactive Bladder (OAB) Therapeutics Price by Application (2021-2026) & (US$/Unit) Table 56. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2027-2032) & (K Units) Table 57. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Application (2027-2032) Table 58. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2027-2032) & (US$ Million) Table 59. Global Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Application (2027-2032) Table 60. Global Overactive Bladder (OAB) Therapeutics Price by Application (2027-2032) & (US$/Unit) Table 61. North America Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 62. North America Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 64. Europe Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 68. Latin America Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 71. Allergan Company Information Table 72. Allergan Business Overview Table 73. Allergan Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio Table 75. Allergan Recent Development Table 76. Astellas Pharma Company Information Table 77. Astellas Pharma Business Overview Table 78. Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio Table 80. Astellas Pharma Recent Development Table 81. Hisamitsu Pharmaceutical Company Information Table 82. Hisamitsu Pharmaceutical Business Overview Table 83. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 85. Hisamitsu Pharmaceutical Recent Development Table 86. Ion Channel Innovations Company Information Table 87. Ion Channel Innovations Business Overview Table 88. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio Table 90. Ion Channel Innovations Recent Development Table 91. Kwang Dong Pharmaceutical Company Information Table 92. Kwang Dong Pharmaceutical Business Overview Table 93. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 95. Kwang Dong Pharmaceutical Recent Development Table 96. ONO Pharmaceutical Company Information Table 97. ONO Pharmaceutical Business Overview Table 98. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 100. ONO Pharmaceutical Recent Development Table 101. Tengion Company Information Table 102. Tengion Business Overview Table 103. Tengion Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio Table 105. Tengion Recent Development Table 106. GlaxoSmithKline Company Information Table 107. GlaxoSmithKline Business Overview Table 108. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio Table 110. GlaxoSmithKline Recent Development Table 111. Ferring Company Information Table 112. Ferring Business Overview Table 113. Ferring Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio Table 115. Ferring Recent Development Table 116. Pfizer Company Information Table 117. Pfizer Business Overview Table 118. Pfizer Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio Table 120. Pfizer Recent Development Table 121. Lanzhou Institute of Biological Products Company Information Table 122. Lanzhou Institute of Biological Products Business Overview Table 123. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio Table 125. Lanzhou Institute of Biological Products Recent Development Table 126. Merck Company Information Table 127. Merck Business Overview Table 128. Merck Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Merck Overactive Bladder (OAB) Therapeutics Product Portfolio Table 130. Merck Recent Development Table 131. Sanofi Company Information Table 132. Sanofi Business Overview Table 133. Sanofi Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio Table 135. Sanofi Recent Development Table 136. Teva Pharmaceutical Industries Company Information Table 137. Teva Pharmaceutical Industries Business Overview Table 138. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio Table 140. Teva Pharmaceutical Industries Recent Development Table 141. North America Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 143. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) Table 144. North America Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2027-2032) & (K Units) Table 145. North America Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 146. North America Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. North America Overactive Bladder (OAB) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 148. North America Overactive Bladder (OAB) Therapeutics Market Share by Country (2021-2026) Table 149. North America Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. North America Overactive Bladder (OAB) Therapeutics Market Share Forecast by Country (2027-2032) Table 151. Europe Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 153. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) Table 154. Europe Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2027-2032) & (K Units) Table 155. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 156. Europe Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Europe Overactive Bladder (OAB) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 158. Europe Overactive Bladder (OAB) Therapeutics Market Share by Country (2021-2026) Table 159. Europe Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Europe Overactive Bladder (OAB) Therapeutics Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 163. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) Table 164. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2027-2032) & (K Units) Table 165. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 166. Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 168. Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Share by Country (2021-2026) Table 169. Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Share Forecast by Country (2027-2032) Table 171. Latin America Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. Latin America Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 173. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) Table 174. Latin America Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2027-2032) & (K Units) Table 175. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 176. Latin America Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Latin America Overactive Bladder (OAB) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 178. Latin America Overactive Bladder (OAB) Therapeutics Market Share by Country (2021-2026) Table 179. Latin America Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Latin America Overactive Bladder (OAB) Therapeutics Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 183. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) Table 184. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2027-2032) & (K Units) Table 185. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 186. Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 188. Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Share by Country (2021-2026) Table 189. Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Share Forecast by Country (2027-2032) Table 191. Key Raw Materials Table 192. Raw Materials Key Suppliers Table 193. Overactive Bladder (OAB) Therapeutics Distributors List Table 194. Overactive Bladder (OAB) Therapeutics Customers List Table 195. Research Programs/Design for This Report Table 196. Authors List of This Report Table 197. Secondary Sources Table 198. Primary Sources List of Figures Figure 1. Overactive Bladder (OAB) Therapeutics Image Figure 2. Global Overactive Bladder (OAB) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Overactive Bladder (OAB) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Overactive Bladder (OAB) Therapeutics Sales (2021-2032) & (K Units) Figure 5. Anticholinergic Agents Image Figure 6. Global Anticholinergic Agents Sales YoY Growth (2021-2032) & (K Units) Figure 7. Beta-3 Adrenoreceptor Agonists Image Figure 8. Global Beta-3 Adrenoreceptor Agonists Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Overactive Bladder (OAB) Therapeutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Overactive Bladder (OAB) Therapeutics Market Share by Type 2025 VS 2032 Figure 11. North America Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Type in 2025 Figure 12. North America Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Type in 2025 Figure 13. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Type in 2025 Figure 14. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Type in 2025 Figure 17. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Overactive Bladder (OAB) Therapeutics Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hosptial Image Figure 24. Global Hosptial Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinci Image Figure 26. Global Clinci Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Overactive Bladder (OAB) Therapeutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Overactive Bladder (OAB) Therapeutics Market Share by Application 2025 VS 2032 Figure 31. North America Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Application in 2025 Figure 32. North America Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Application in 2025 Figure 33. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Application in 2025 Figure 34. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Application in 2025 Figure 37. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share in Value by Application in 2025 Figure 41. North America Overactive Bladder (OAB) Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Overactive Bladder (OAB) Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Overactive Bladder (OAB) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Overactive Bladder (OAB) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Overactive Bladder (OAB) Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Overactive Bladder (OAB) Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Overactive Bladder (OAB) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Overactive Bladder (OAB) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Overactive Bladder (OAB) Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Overactive Bladder (OAB) Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Overactive Bladder (OAB) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Overactive Bladder (OAB) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Overactive Bladder (OAB) Therapeutics Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Overactive Bladder (OAB) Therapeutics Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Anticholinergic Agents
  • Beta-3 Adrenoreceptor Agonists
Applications
  • Hosptial
  • Clinci
  • Other
Companies covered
  • Allergan
  • Astellas Pharma
  • Hisamitsu Pharmaceutical
  • Ion Channel Innovations
  • Kwang Dong Pharmaceutical
  • ONO Pharmaceutical
  • Tengion
  • GlaxoSmithKline
  • Ferring
  • Pfizer
  • Lanzhou Institute of Biological Products
  • Merck
  • Sanofi
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Overactive Bladder (OAB) Therapeutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Overactive Bladder (OAB) Therapeutics Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Overactive Bladder (OAB) Therapeutics Market by Type
  6. 1.3.1 Anticholinergic Agents
  7. 1.3.2 Beta-3 Adrenoreceptor Agonists
  8. 1.4 Global Overactive Bladder (OAB) Therapeutics Market Size by Type
  9. 1.4.1 Global Overactive Bladder (OAB) Therapeutics Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Overactive Bladder (OAB) Therapeutics Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Overactive Bladder (OAB) Therapeutics Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Overactive Bladder (OAB) Therapeutics Industry Trends
  2. 2.2 Overactive Bladder (OAB) Therapeutics Industry Drivers
  3. 2.3 Overactive Bladder (OAB) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Overactive Bladder (OAB) Therapeutics Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Overactive Bladder (OAB) Therapeutics Revenue (2021-2026)
  2. 3.2 Global Top Players by Overactive Bladder (OAB) Therapeutics Sales (2021-2026)
  3. 3.3 Global Top Players by Overactive Bladder (OAB) Therapeutics Price (2021-2026)
  4. 3.4 Global Overactive Bladder (OAB) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Overactive Bladder (OAB) Therapeutics Major Company Production Sites & Headquarters
  6. 3.6 Global Overactive Bladder (OAB) Therapeutics Company, Product Type & Application
  7. 3.7 Global Overactive Bladder (OAB) Therapeutics Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Overactive Bladder (OAB) Therapeutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Overactive Bladder (OAB) Therapeutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Overactive Bladder (OAB) Therapeutics Tier 1, Tier 2, and Tier 3
4 Overactive Bladder (OAB) Therapeutics Regional Status and Outlook
  1. 4.1 Global Overactive Bladder (OAB) Therapeutics Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Overactive Bladder (OAB) Therapeutics Historic Market Size by Region
  3. 4.2.1 Global Overactive Bladder (OAB) Therapeutics Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Overactive Bladder (OAB) Therapeutics Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Overactive Bladder (OAB) Therapeutics Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Overactive Bladder (OAB) Therapeutics Forecasted Market Size by Region
  7. 4.3.1 Global Overactive Bladder (OAB) Therapeutics Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Overactive Bladder (OAB) Therapeutics Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Overactive Bladder (OAB) Therapeutics Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Overactive Bladder (OAB) Therapeutics by Application
  1. 5.1 Overactive Bladder (OAB) Therapeutics Market by Application
  2. 5.1.1 Hosptial
  3. 5.1.2 Clinci
  4. 5.1.3 Other
  5. 5.2 Global Overactive Bladder (OAB) Therapeutics Market Size by Application
  6. 5.2.1 Global Overactive Bladder (OAB) Therapeutics Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Overactive Bladder (OAB) Therapeutics Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Overactive Bladder (OAB) Therapeutics Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Allergan
  2. 6.1.1 Allergan Company Information
  3. 6.1.2 Allergan Business Overview
  4. 6.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio
  6. 6.1.5 Allergan Recent Developments
  7. 6.2 Astellas Pharma
  8. 6.2.1 Astellas Pharma Company Information
  9. 6.2.2 Astellas Pharma Business Overview
  10. 6.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio
  12. 6.2.5 Astellas Pharma Recent Developments
  13. 6.3 Hisamitsu Pharmaceutical
  14. 6.3.1 Hisamitsu Pharmaceutical Company Information
  15. 6.3.2 Hisamitsu Pharmaceutical Business Overview
  16. 6.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  18. 6.3.5 Hisamitsu Pharmaceutical Recent Developments
  19. 6.4 Ion Channel Innovations
  20. 6.4.1 Ion Channel Innovations Company Information
  21. 6.4.2 Ion Channel Innovations Business Overview
  22. 6.4.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio
  24. 6.4.5 Ion Channel Innovations Recent Developments
  25. 6.5 Kwang Dong Pharmaceutical
  26. 6.5.1 Kwang Dong Pharmaceutical Company Information
  27. 6.5.2 Kwang Dong Pharmaceutical Business Overview
  28. 6.5.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  30. 6.5.5 Kwang Dong Pharmaceutical Recent Developments
  31. 6.6 ONO Pharmaceutical
  32. 6.6.1 ONO Pharmaceutical Company Information
  33. 6.6.2 ONO Pharmaceutical Business Overview
  34. 6.6.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  36. 6.6.5 ONO Pharmaceutical Recent Developments
  37. 6.7 Tengion
  38. 6.7.1 Tengion Company Information
  39. 6.7.2 Tengion Business Overview
  40. 6.7.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio
  42. 6.7.5 Tengion Recent Developments
  43. 6.8 GlaxoSmithKline
  44. 6.8.1 GlaxoSmithKline Company Information
  45. 6.8.2 GlaxoSmithKline Business Overview
  46. 6.8.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio
  48. 6.8.5 GlaxoSmithKline Recent Developments
  49. 6.9 Ferring
  50. 6.9.1 Ferring Company Information
  51. 6.9.2 Ferring Business Overview
  52. 6.9.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio
  54. 6.9.5 Ferring Recent Developments
  55. 6.10 Pfizer
  56. 6.10.1 Pfizer Company Information
  57. 6.10.2 Pfizer Business Overview
  58. 6.10.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio
  60. 6.10.5 Pfizer Recent Developments
  61. 6.11 Lanzhou Institute of Biological Products
  62. 6.11.1 Lanzhou Institute of Biological Products Company Information
  63. 6.11.2 Lanzhou Institute of Biological Products Business Overview
  64. 6.11.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio
  66. 6.11.5 Lanzhou Institute of Biological Products Recent Developments
  67. 6.12 Merck
  68. 6.12.1 Merck Company Information
  69. 6.12.2 Merck Business Overview
  70. 6.12.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Merck Overactive Bladder (OAB) Therapeutics Product Portfolio
  72. 6.12.5 Merck Recent Developments
  73. 6.13 Sanofi
  74. 6.13.1 Sanofi Company Information
  75. 6.13.2 Sanofi Business Overview
  76. 6.13.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio
  78. 6.13.5 Sanofi Recent Developments
  79. 6.14 Teva Pharmaceutical Industries
  80. 6.14.1 Teva Pharmaceutical Industries Company Information
  81. 6.14.2 Teva Pharmaceutical Industries Business Overview
  82. 6.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio
  84. 6.14.5 Teva Pharmaceutical Industries Recent Developments
7 North America by Country
  1. 7.1 North America Overactive Bladder (OAB) Therapeutics Sales by Country
  2. 7.1.1 North America Overactive Bladder (OAB) Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026)
  4. 7.1.3 North America Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2027-2032)
  5. 7.2 North America Overactive Bladder (OAB) Therapeutics Market Size by Country
  6. 7.2.1 North America Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Overactive Bladder (OAB) Therapeutics Market Size by Country (2021-2026)
  8. 7.2.3 North America Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Country
  2. 8.1.1 Europe Overactive Bladder (OAB) Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026)
  4. 8.1.3 Europe Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Overactive Bladder (OAB) Therapeutics Market Size by Country
  6. 8.2.1 Europe Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Overactive Bladder (OAB) Therapeutics Market Size by Country (2021-2026)
  8. 8.2.3 Europe Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales by Country
  2. 9.1.1 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size by Country
  6. 9.2.1 Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Overactive Bladder (OAB) Therapeutics Sales by Country
  2. 10.1.1 South America Overactive Bladder (OAB) Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026)
  4. 10.1.3 South America Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2027-2032)
  5. 10.2 South America Overactive Bladder (OAB) Therapeutics Market Size by Country
  6. 10.2.1 South America Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Overactive Bladder (OAB) Therapeutics Market Size by Country (2021-2026)
  8. 10.2.3 South America Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country
  2. 11.1.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size by Country
  6. 11.2.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Overactive Bladder (OAB) Therapeutics Value Chain Analysis
  2. 12.1.1 Overactive Bladder (OAB) Therapeutics Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Overactive Bladder (OAB) Therapeutics Production Mode & Process
  7. 12.2 Overactive Bladder (OAB) Therapeutics Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Overactive Bladder (OAB) Therapeutics Distributors
  10. 12.2.3 Overactive Bladder (OAB) Therapeutics Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst